Newer antiarrhythmic agents for patients with coronary artery disease.
D000070:Acebutolol / Q000627:therapeutic use; D000328:Adult; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality; D003645:Death, Sudden; D004562:Electrocardiography; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011379:Prognosis; D014693:Ventricular Fibrillation / Q000209:etiology
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010919:Placebos; D000070:Acebutolol; D010208:Papaverine